Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

NCT05181124 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Anti-Ulcer Agents

Interventions

DRUG: coadministration of JP-1366 and aceclofenac
DRUG: coadministration of JP-1366 and meloxicam
DRUG: coadministration of JP-1366 and naproxen
DRUG: single-dosing of JP-1366 in Korean and Caucasian

Sponsor

Onconic Therapeutics Inc.